App-Quantinova.ai

Variation in the administration of early chemotherapy for indolent lymphomas: Analysis of the National Cancer Data Base (NCDB).

Jaleh Fallah - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Global Cancer Institute (GCI) multi-disciplinary tumor boards (MTBs) as an educational tool to improve guideline-based cancer clinical practice in low- and middle-income countries (LMICs).

Jessica St. Louis - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Characteristics of successful fertility preservation programs for cancer patients.

Patrick Heiser - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Association of financial hardship with receipt of necessary medical care among adult cancer survivors.

Matthew P. Banegas - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Cancer center staff effort related to electronic patient portal use: A growing demand.

David E. Gerber - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

A qualitative perspective on oncologist attitudes, barriers and strategies to practicing patient- and family-centered care.

Timothy K. Nguyen - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Access to cancer drugs in Europe years 2005-2014.

Nils Erik Wilking - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Utility of comprehensive genomic profiling (CGP) at an NCI-designated cancer center for identifying clinically relevant genomic alterations (CRGA) and implementing genomically directed therapy (GDT).

Talal Hilal - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Impact on health status's primary caregivers of patients with cancer at National Cancer Institute Mexico an unmet need.

Oscar Galindo Vazquez - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Adolescent and young adult (AYA) oncology patients: Disparities in access to specialized cancer centers.

Elysia Marie Alvarez - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

High cost-related medication non-adherence among diabetic cancer patients.

James Zhang - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Defining the characteristics of medical oncology patients requiring inpatient hospital admission.

Krish Patel - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Hematopoietic cell transplantation (HCT) in older patients with acute myeloid leukemia (AML).

Vijaya Raj Bhatt - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Determinants of receipt of hematopoietic cell transplantation (HCT) in younger patients with acute myeloid leukemia (AML).

Vijaya Raj Bhatt - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

An analysis of clinical trials in clinicaltrials.gov to assess the scope of NCI support and inclusion on NCIs cancer.gov website.

Grace Miskin - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Barriers to cancer care pathways in France: A qualitative case study.

Fatima Yatim - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Oxaliplatin associated neurotoxicity outcomes among older adults with colorectal cancer: a population-based study.

Michael J. Raphael - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Oxaliplatin

A patient-reported outcome driven case management system for hematology/oncology patients.

Rahma M. Warsame - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Optimizing Genotype Matched Clinical Trial (GMCT) accrual in a community oncology program (COP).

Steven Francis Powell - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

The impact of comprehensive genomic profiling in the management of patients with metastatic solid tumors in a developing country.

Pablo M. Barrios - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Methadone hydrochloride

Filters

41730 Abstracts